Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

NCT03436732 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
5
Enrollment
NIH
Sponsor class

Stopped Due to fatal occurrence (pneumonitis) attributed to one of the study drugs.

Conditions

Interventions

Sponsor

National Cancer Institute (NCI)